Examining the use of ceftaroline in the treatment of streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2428-2431

  Sakoulas, George ^a   Nonejuie, Poochit ^b   Kullar, Ravina ^c   Pogliano, Joseph ^b   Rybak, Michael J ^d   Nizet, Victor ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAROLINE; CEFTRIAXONE; LINEZOLID; PENICILLIN DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CEPHALOSPORIN DERIVATIVE; CYTOCHROME C;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEVER; HUMAN; IN VITRO STUDY; LEUKOCYTOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS MENINGITIS; STAPHYLOCOCCUS INFECTION; SURFACE CHARGE; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; DRUG INTERACTION; FEMALE; MALE; MENINGITIS, PNEUMOCOCCAL; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CEPHALOSPORINS; CYTOCHROMES C; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS;

EID: 84949154503     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04965-14     Document Type: Article

References (14)

1. Steed ME, Rybak MJ. 2010. Ceftaroline: A new cephalosporin with activity against resistant Gram-positive pathogens. Pharmacotherapy 30:375- 389. http://dx.doi.org/10.1592/phco.30.4.375.
2. Shorr AF, Kollef M, Eckburg PB, Liorens L, Friedland HD. 2013. Assessment of ceftaroline fosamil in the treatment of communityacquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials. Diagn Microbiol Infect Dis 75:298-303. http://dx.doi.org/10.1016/j.diagmicrobio.2012.12.002.
3. Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ. 2012. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 56:2691. http://dx.doi.org/10.1128/AAC.06185-11.
4. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2014. Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers. Antimicrob Agents Chemother 58: 2468-2471. http://dx.doi.org/10.1128/AAC.02557-13.
5. Croisier-Bertin D, Piroth L, Charles P, Larribeau A, Biek D, Ge Y, Chavanet P. 2011. Ceftaroline versus ceftriaxone in a highly penicillinresistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother 55:3557. http://dx.doi.org/10 .1128/AAC.01773-09.
6. Cottagnoud P, Cottagnoud M, Acosta F, Stucki AA. 2013. Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant Streptococcus pneumoniae in an experimental rabbit meningitis model. Antimicrob Agents Chemother 57:4653-4655. http://dx.doi.org/10.1128/AAC.00286-13.
7. Lanie JA, Ng WL, Kazmierczak KM, Andrzejewski TM, Davidsen TM, Wayne KJ, Tettelin H, Glass JI, Winkler ME. 2007. Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol 189:38-51. http://dx.doi.org/10.1128/JB.01148-06.
8. Sakoulas G, Rose WE, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. 2014. Ceftaroline restores daptomycin activity of daptomycinresistant vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 58:1494-1500. http://dx.doi.org/10.1128/AAC.02274-13.
9. Kuriakose SS, Rabbat M, Gallagher JC. 2015. Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother 70:953-954. http://dx.doi.org/10.1093/jac/dku464.
10. Byfield FJ, Wen Q, Lesczynska K, Kulakowska A, Namiot Z, Janmey PA, Bucki R. 2011. Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability. Am J Physiol Cell Physiol 300: C105-C112. http://dx.doi.org/10.1152/ajpcell.00158.2010.
11. Merres J, Höss J, Albrecht LJ, Kress E, Soehnlein O, Jansen S, Pufe T, Tauber SC, Brandenburg LO. 2014. Role of the cathelicidin-related antimicrobial peptide in inflammation and mortality in a mouse model of bacterial meningitis. J Innate Immun 6:205-218. http://dx.doi.org/10.1159/000353645.
12. Dandache P, Nicolau DP, Sakoulas G. 2009. Tigecycline for the treatment of multidrug-resistant Klebsiella pneumoniae meningitis. Infect Dis Clin Practice 17:66-68. http://dx.doi.org/10.1097/IPC.0b013e318181fa38.
13. Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V. 2014. Nafcillin enhances innate immune-mediated killing of methicillinresistant Staphylococcus aureus. J Mol Med (Berl) 92:139-149. http://dx.doi.org/10.1007/s00109-013-1100-7.
14. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin- And cationic host defense peptide-mediate killing of ampicillin and vancomycin- resistant Enterococcus faecium. Antimicrob Agents Chemother 56: 838-844. http://dx.doi.org/10.1128/AAC.05551-11.